학술논문
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.
Document Type
article
Author
Walter, Nicholas D; Born, Sarah EM; Robertson, Gregory T; Reichlen, Matthew; Dide-Agossou, Christian; Ektnitphong, Victoria A; Rossmassler, Karen; Ramey, Michelle E; Bauman, Allison A; Ozols, Victor; Bearrows, Shelby C; Schoolnik, Gary; Dolganov, Gregory; Garcia, Benjamin; Musisi, Emmanuel; Worodria, William; Huang, Laurence; Davis, J Lucian; Nguyen, Nhung V; Nguyen, Hung V; Nguyen, Anh TV; Phan, Ha; Wilusz, Carol; Podell, Brendan K; Sanoussi, N' Dira; de Jong, Bouke C; Merle, Corinne S; Affolabi, Dissou; McIlleron, Helen; Garcia-Cremades, Maria; Maidji, Ekaterina; Eshun-Wilson, Franceen; Aguilar-Rodriguez, Brandon; Karthikeyan, Dhuvarakesh; Mdluli, Khisimuzi; Bansbach, Cathy; Lenaerts, Anne J; Savic, Radojka M; Nahid, Payam; Vásquez, Joshua J; Voskuil, Martin I
Source
Nature communications. 12(1)
Subject
Language
Abstract
There is urgent need for new drug regimens that more rapidly cure tuberculosis (TB). Existing TB drugs and regimens vary in treatment-shortening activity, but the molecular basis of these differences is unclear, and no existing assay directly quantifies the ability of a drug or regimen to shorten treatment. Here, we show that drugs historically classified as sterilizing and non-sterilizing have distinct impacts on a fundamental aspect of Mycobacterium tuberculosis physiology: ribosomal RNA (rRNA) synthesis. In culture, in mice, and in human studies, measurement of precursor rRNA reveals that sterilizing drugs and highly effective drug regimens profoundly suppress M. tuberculosis rRNA synthesis, whereas non-sterilizing drugs and weaker regimens do not. The rRNA synthesis ratio provides a readout of drug effect that is orthogonal to traditional measures of bacterial burden. We propose that this metric of drug activity may accelerate the development of shorter TB regimens.